Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma

June 1st 2020

Saad Usmani, MD, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.

Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment

May 31st 2020

Teclistamab (JNJ-64007957) appeared to be a safe and efficacious treatment for patients with relapsed/refractory multiple myeloma.

CC-92480 Shows Encouraging Efficacy in First-in-Human Study for R/R Multiple Myeloma

May 30th 2020

An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma.

Idecabtagene Vicleucel Highly Active in Heavily Pretreated Myeloma

May 30th 2020

Idecabtagene vicleucel induced a response in nearly three-fourths of patients with heavily pretreated relapsed/refractory multiple myeloma, according to topline findings from the pivotal phase 2 KarMMA trial.

Dr. Weitzman on Reusing Treatments in Relapsed/Refractory Multiple Myeloma

May 30th 2020

James Weitzman, MD, discusses reusing treatments in patients with relapsed/refractory multiple myeloma.

Dr. Berdeja on Updated CARTITUDE-1 Results in Multiple Myeloma

May 29th 2020

Jesus Berdeja, MD, discusses updated results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) in multiple myeloma.

Selinexor Triplet Improves Response, Reduces Neuropathy in Relapsed/Refractory Multiple Myeloma

May 29th 2020

When added to bortezomib and dexamethasone in patients with multiple myeloma, selinexor, an inhibitor of XPO1-mediated nuclear export, improves progression-free survival and overall response rate and reduces the incidence of peripheral neuropathy.

Promising Responses Seen With Belantamab Mafodotin Triplet for R/R Multiple Myeloma

May 29th 2020

Belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (B-Vd) demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma.

Belantamab Mafodotin Signals Durable Responses in Relapsed/Refractory Myeloma

May 29th 2020

Single agent belantamab mafodotin sustained clinically meaningful deep responses and was well tolerated in patients with heavily pretreated relapsed or refractory multiple myeloma.

Dr. Munshi on the Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

May 29th 2020

Nikhil C. Munshi, MD, discusses the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Dr. Lonial on the Results of the DREAMM-2 Trial in Multiple Myeloma

May 29th 2020

Sagar Lonial, MD, FACP, discusses the results of the phase 2 DREAMM-2 trial in multiple myeloma.

Carfilzomib Triplet Does Not Improve Outcomes Versus Standard of Care in Newly Diagnosed Myeloma

May 29th 2020

The combination of next-generation proteasome inhibitor carfilzomib, lenalidomide, and dexamethasone did not show a superiority in progression-free survival in patients with newly diagnosed multiple myeloma when compared with the current standard of care triplet of bortezomib, lenalidomide and dexamethasone.

Dr. O'Donnell on Transplant Considerations in Multiple Myeloma

May 29th 2020

Betsy O'Donnell, MD, discusses transplant considerations in patients with multiple myeloma.

Dr. Branagan on the Role of Transplant in High-Risk Multiple Myeloma

May 28th 2020

Andrew Branagan, MD, discusses the role of autologous stem cell transplantation in patients with high-risk multiple myeloma.

Dr. Morgan on Treatment Selection in Multiple Myeloma

May 22nd 2020

Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.

FDA Approval Insights: Subcutaneous Daratumumab in Multiple Myeloma

May 21st 2020

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

Dr. Yee on the Results of the CANDOR Trial in Relapsed/Refractory Myeloma

May 20th 2020

Andrew Yee, MD, discusses the phase 3 CANDOR trial in relapsed/refractory multiple myeloma.

Selinexor sNDA Submitted to FDA for Earlier Use in Multiple Myeloma

May 20th 2020

A supplemental New Drug Application has been submitted to the FDA for the use of selinexor as a treatment for patients with multiple myeloma following at least 1 line of prior therapy.

Selinexor sNDA Submitted to FDA for Earlier Use in Multiple Myeloma

May 20th 2020

A supplemental New Drug Application has been submitted to the FDA for the use of selinexor as a treatment for patients with multiple myeloma following at least 1 line of prior therapy.

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

May 20th 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.